Home > Insider Trading > Filing (0000899243-22-029282)

Filing Details

Accession Number:: 0000899243-22-029282
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-08-19 16:39:43
Reporting Period:: 2022-08-17

Accepted Time:: 2022-08-19 16:39:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831828	Vera Therapeutics Inc.	VERA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
933790	Tc Group, Llc	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1354120	Carlyle Investment Management Llc	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1397144	Llp Abingworth	38 Jermyn Street, London, England X0 SW1Y 6DN	No	No	Yes	No
1527166	Carlyle Group Inc.	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1548626	Carlyle Holdings I Gp Inc.	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1548627	L.l.c. Sub Gp I Holdings Carlyle	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1548628	L.p. I Holdings Carlyle	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1790577	L.l.c. Holdings Subsidiary Cg	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No
1811412	Abingworth Bioventures 8 Lp	38 Jermyn Street, London, England X0 SW1Y 6DN	No	No	Yes	No
1941860	Carlyle Genesis Uk Llc	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2022-08-17	9,925	$11.00	2,970,156	No	4	M	Indirect	See footnotes
Class A Common Stock	Disposition	2022-08-17	3,281	$19.88	2,966,875	No	4	S	Indirect	See footnotes
Class A Common Stock	Disposition	2022-08-17	6,472	$20.42	2,960,403	No	4	S	Indirect	See footnotes
Class A Common Stock	Disposition	2022-08-17	172	$21.07	2,960,231	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (right to buy)	Disposition	2022-08-17	9,925	$0.00	9,925	$11.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2031-05-12	No	4	M	Indirect

Footnotes

Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8.
The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option is fully vested and exercisable.
Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP.